In the market the company is trading up by 8.11% percent from yesterday’s close giving it a place as a top gainer in the market today. 549 shares have been traded.
Traders are a little more bearish on Glycomimetics Inc of late looking at the motion in short interest. The company had a rise in short interest from September 29, 2017 to October 13, 2017 of 11.58%. Short interest increased 370,153 over that period. Days to cover increased from 5.0 to 6.0 and the short interest percentage is 0.17% as of October 13.
Here is a rundown on some insider market activity for Glycomimetics Inc (:GLYC). SVP Clinical Development, CMO Helen M. Thackray sold 2,000 shares at an average price of $13.00 on Mon the 18th. Thackray now owns $1,957,995 of stock per an SEC filing yesterday.
A few notable investment firms have updated their holdings. As of the end of the quarter Ubs Group Ag had disposed of a total of 171 shares trimming its position 57.0%. The value in dollars went from $2,000 to $1,000 a change of 50.0% quarter to quarter. As of quarter end Cutler Group LP had sold 600 shares trimming its stake by 85.7%. The value of the investment in (GLYC) decreased from $7,000 to $0 a change of $7,000 quarter over quarter.
Meeder Asset Management Inc cut its stake by shedding 335 shares a decrease of 76.3%. Meeder Asset Management Inc now controls 104 shares worth $1,000. The value of the position overall is down by 80.0%. Simplex Trading, LLC augmented its investment by buying 12,222 shares an increase of 643.6% from 06/30/2017 to 09/30/2017. Simplex Trading, LLC owns 14,121 shares valued at $197,000. The total value of its holdings increased 838.1%.
The P/E ratio is and the market cap of the company is 396.21M.
GlycoMimetics, Inc., launched on April 4, 2003, is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and potentially other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. GMI-1359 is undergoing testing in preclinical models from which it intends to select a target clinical indication, in oncology. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9, which have potential to be used for the treatment of fibrosis, cancer and cardiovascular disease..